Atropine in Ophthalmic Applications: A Comprehensive Review of Mechanisms, Efficacy, and Safety

Abstract

Atropine, a non-selective muscarinic antagonist, has a long history of use in ophthalmology, primarily for cycloplegia and mydriasis. However, its repurposing as a potential therapeutic agent for myopia control has garnered significant attention in recent years. This review aims to provide a comprehensive overview of atropine’s mechanisms of action, efficacy at various dosages, short-term and long-term side effects, ideal candidates for treatment, and comparisons with other myopia control methods. Furthermore, it explores novel applications of atropine beyond myopia management, including its potential role in treating amblyopia and other ophthalmic conditions. We critically evaluate the existing literature, highlighting areas of consensus and controversy, and identify knowledge gaps requiring further research.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Atropine, a naturally occurring alkaloid derived from plants of the Atropa genus, acts as a non-selective antagonist of muscarinic acetylcholine receptors (mAChRs). Its anticholinergic properties have made it a mainstay in ophthalmology for inducing cycloplegia (paralysis of accommodation) and mydriasis (pupil dilation), facilitating accurate refractive error assessment and fundus examination. Historically, concerns regarding side effects associated with full-strength atropine (1%) have limited its widespread adoption for long-term use. However, recent studies demonstrating the efficacy of low-dose atropine (0.01%-0.05%) in slowing myopia progression have revolutionized its application in pediatric ophthalmology.

Myopia, or nearsightedness, is a global public health concern with increasing prevalence, particularly in East Asia. Its progression is associated with significant ocular morbidity, including retinal detachment, myopic maculopathy, and glaucoma. The search for effective myopia control strategies has led to the investigation of various interventions, including orthokeratology, multifocal soft contact lenses, and pharmacologic agents such as atropine. While orthokeratology and multifocal contact lenses alter peripheral retinal image characteristics, atropine exerts its effect through a different, and not completely understood, mechanism.

This review consolidates current knowledge regarding atropine’s role in ophthalmology, extending beyond myopia control to encompass its multifaceted applications. It delves into the intricate pharmacological mechanisms underlying its therapeutic effects, meticulously examines the dosage-dependent efficacy and safety profiles, and critically evaluates its position relative to other myopia control strategies. Furthermore, it investigates emerging research exploring the potential of atropine in treating amblyopia and other ocular conditions, providing a holistic perspective on this versatile drug.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Mechanisms of Action in Myopia Control

The precise mechanism by which atropine slows myopia progression remains a subject of ongoing investigation and debate. Several hypotheses have been proposed, but none fully explain the observed clinical effects. These proposed mechanisms can be broadly categorized into two main areas: accommodation-related effects and non-accommodation-related effects, encompassing retinal and scleral pathways.

2.1 Accommodation-Related Effects

The traditional explanation for atropine’s myopia control effect centers on its cycloplegic action. By paralyzing the ciliary muscle, atropine eliminates accommodative lag, which has been implicated in driving myopia progression. Accommodative lag occurs when the eye fails to focus accurately on near objects, leading to blurred retinal images. This chronic blur is hypothesized to stimulate excessive eye growth in an attempt to bring the image into focus. However, the efficacy of low-dose atropine, which induces minimal cycloplegia, challenges this theory. Studies have shown that the degree of cycloplegia induced by low-dose atropine does not correlate strongly with its myopia control effect, suggesting that other mechanisms are at play.

2.2 Non-Accommodation-Related Effects

2.2.1 Retinal Pathways: Emerging evidence suggests that atropine may exert its effect directly on the retina. The retina contains muscarinic acetylcholine receptors (mAChRs), and atropine’s antagonism of these receptors may influence retinal signaling pathways involved in eye growth regulation. Specifically, studies have demonstrated the presence of mAChRs on retinal amacrine, ganglion, and photoreceptor cells. Atropine’s interaction with these receptors could modulate the release of various neurotransmitters and signaling molecules, such as dopamine and nitric oxide, which have been implicated in regulating scleral remodeling and eye growth.

Dopamine Hypothesis: Dopamine, a neurotransmitter released by retinal amacrine cells, is known to inhibit eye growth. Atropine may indirectly increase dopamine levels in the retina, thereby suppressing myopia progression. Studies have shown that dopamine antagonists can reverse the myopia-inhibiting effect of atropine in animal models, supporting this hypothesis. However, human studies directly measuring retinal dopamine levels in response to atropine are lacking.

Nitric Oxide Hypothesis: Nitric oxide (NO), a potent vasodilator and signaling molecule, is also produced in the retina. NO is involved in various physiological processes, including the regulation of blood flow and neuronal signaling. Some studies suggest that NO may promote scleral remodeling and eye growth. Atropine may reduce NO production in the retina, thereby inhibiting myopia progression. However, the precise role of NO in atropine’s mechanism of action remains unclear.

2.2.2 Scleral Pathways: The sclera, the outer coat of the eye, plays a critical role in determining eye shape and size. Myopia is characterized by excessive scleral growth, leading to elongation of the eyeball. Atropine may directly affect scleral fibroblasts, the cells responsible for producing and maintaining the scleral extracellular matrix. In vitro studies have shown that atropine can inhibit scleral fibroblast proliferation and collagen synthesis. These findings suggest that atropine may directly modulate scleral remodeling, preventing excessive eye elongation.

2.2.3 Choroidal Pathways: The choroid, a vascular layer located between the retina and sclera, also plays a role in eye growth regulation. Changes in choroidal thickness have been observed in response to accommodation and defocus. Atropine may influence choroidal blood flow and thickness, thereby affecting eye growth. However, the precise role of the choroid in atropine’s mechanism of action remains poorly understood.

2.3 Integrated Model

A comprehensive understanding of atropine’s mechanism of action likely involves an integrated model that incorporates both retinal and scleral pathways. Atropine may act on retinal mAChRs to modulate the release of various neurotransmitters and signaling molecules, which in turn influence scleral remodeling and eye growth. Further research is needed to fully elucidate the complex interactions between these pathways.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Dosage-Dependent Efficacy and Safety

The efficacy and safety of atropine in myopia control are highly dependent on the dosage used. While high-dose atropine (1%) has been shown to be effective in slowing myopia progression, it is associated with significant side effects, including blurred vision, photophobia, and allergic reactions. Low-dose atropine (0.01%-0.05%) has emerged as a promising alternative, offering a balance between efficacy and tolerability.

3.1 Efficacy at Different Dosages

Numerous clinical trials have investigated the efficacy of atropine at different dosages in slowing myopia progression. The ATOM (Atropine for the Treatment of Myopia) studies, conducted in Singapore, have been pivotal in establishing the efficacy of low-dose atropine. ATOM1 demonstrated that 1% atropine was effective in slowing myopia progression but was associated with significant side effects. ATOM2 compared the efficacy of 0.5%, 0.1%, and 0.01% atropine and found that 0.01% atropine had a comparable myopia control effect to higher concentrations with fewer side effects. Subsequent studies have confirmed the efficacy of 0.01% atropine in diverse populations. Meta-analyses of multiple clinical trials have shown that low-dose atropine is effective in slowing both refractive error progression and axial elongation, a key indicator of myopia progression.

Dosage and efficacy may also vary based on race/ethnicity, with some evidence suggesting differing responses among different populations. More research is needed to understand the optimal dosage across different ethnic groups.

3.2 Short-Term Side Effects

The most common short-term side effects of atropine include blurred vision, photophobia, and allergic reactions. Blurred vision is primarily due to cycloplegia, which impairs accommodation. Photophobia is caused by mydriasis, which increases the amount of light entering the eye. Allergic reactions, such as conjunctivitis and dermatitis, are less common but can occur in susceptible individuals. The severity of these side effects is generally dose-dependent, with higher concentrations of atropine causing more pronounced side effects. Low-dose atropine is associated with minimal cycloplegia and mydriasis, resulting in fewer and less severe side effects.

3.3 Long-Term Side Effects

The long-term safety of atropine remains a concern, particularly with prolonged use in children. Potential long-term side effects include:

• Pupil Size and Accommodation: Prolonged use of atropine may lead to persistently dilated pupils and impaired accommodation, even after discontinuation of treatment. This could affect visual performance, particularly at near distances.
• Angle Closure Glaucoma: Atropine-induced mydriasis can precipitate angle closure glaucoma in individuals with narrow anterior chamber angles. This is a rare but serious complication that can lead to irreversible vision loss. Careful screening of patients for narrow angles is essential before initiating atropine treatment.
• Systemic Effects: Although atropine is administered topically, systemic absorption can occur, potentially leading to systemic side effects such as dry mouth, urinary retention, and constipation. These side effects are more likely to occur with higher doses of atropine and are generally mild and transient.
• Rebound Effect: A rebound effect, characterized by an accelerated rate of myopia progression after discontinuation of atropine, has been observed in some studies. The mechanisms underlying this rebound effect are not fully understood. Some suggest a gradual tapering of the atropine dosage may mitigate this effect, but this remains an area of active investigation.

Long-term studies are needed to fully assess the long-term safety of low-dose atropine and to determine the optimal duration of treatment.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Ideal Candidates for Atropine Treatment

The selection of appropriate candidates for atropine treatment is crucial for maximizing efficacy and minimizing the risk of side effects. Factors to consider include age, refractive error, rate of myopia progression, and presence of risk factors for adverse events.

4.1 Age

Atropine treatment is generally initiated in children aged 6-12 years, as this is the period of most rapid myopia progression. However, some studies have included younger children, and the optimal age for initiating treatment remains a topic of debate. Older children and adolescents may also benefit from atropine treatment, although the efficacy may be lower compared to younger children. Some evidence suggests that earlier intervention may lead to better long-term outcomes.

4.2 Refractive Error and Rate of Myopia Progression

Atropine treatment is typically recommended for children with moderate to high myopia (e.g., -1.00 to -6.00 diopters) and a history of rapid myopia progression (e.g., -0.50 diopters per year or more). Children with mild myopia and slow progression may not require atropine treatment. The rate of myopia progression should be carefully monitored to assess the need for intervention.

4.3 Risk Factors for Adverse Events

Before initiating atropine treatment, it is essential to screen patients for risk factors for adverse events, such as narrow anterior chamber angles, history of allergic reactions, and systemic conditions that may be exacerbated by anticholinergic medications. Patients with narrow angles should undergo gonioscopy to assess the risk of angle closure glaucoma. Patients with a history of allergic reactions should be carefully monitored for signs of hypersensitivity. Patients with systemic conditions, such as urinary retention or constipation, should be closely monitored for exacerbation of their symptoms.

4.4 Patient Education and Informed Consent

Patient education is crucial for ensuring adherence to treatment and minimizing the risk of side effects. Patients and their parents should be informed about the potential benefits and risks of atropine treatment, as well as alternative myopia control strategies. They should also be instructed on how to administer the eye drops correctly and how to manage any side effects that may occur. Informed consent should be obtained before initiating treatment.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Comparisons with Other Myopia Control Methods

Atropine is one of several myopia control methods available, including orthokeratology, multifocal soft contact lenses, and spectacle lenses designed to slow progression. Each method has its own advantages and disadvantages, and the choice of treatment should be individualized based on the patient’s needs and preferences.

5.1 Orthokeratology

Orthokeratology involves wearing specially designed rigid gas-permeable contact lenses overnight to reshape the cornea. This temporarily reduces myopia and allows for clear vision during the day without the need for glasses or contact lenses. Orthokeratology has been shown to be effective in slowing myopia progression, but it is associated with a risk of corneal infection and other complications. Furthermore, the long-term effects of corneal reshaping are not fully understood.

5.2 Multifocal Soft Contact Lenses

Multifocal soft contact lenses have alternating zones of distance and near correction. These lenses create a myopic defocus in the periphery of the retina, which is thought to slow eye growth. Multifocal soft contact lenses are generally well-tolerated and are associated with a lower risk of corneal infection compared to orthokeratology. However, some patients may experience visual disturbances, such as halos or glare.

5.3 Spectacle Lenses

Special spectacle lenses, such as defocus incorporated multiple segments (DIMS) lenses and highly aspherical lenslets (HAL) lenses, have been developed to create myopic defocus in the periphery of the retina. These lenses are non-invasive and are associated with a low risk of complications. However, some patients may find the lenses cosmetically unappealing.

5.4 Atropine vs. Other Methods

Comparative studies have shown that atropine is generally more effective than orthokeratology and multifocal soft contact lenses in slowing myopia progression. However, atropine is associated with a higher risk of side effects. The choice of treatment should be based on a careful consideration of the risks and benefits of each method.

Combination therapy, involving the use of atropine in conjunction with other myopia control methods such as orthokeratology or multifocal contact lenses, is an emerging area of research. Some studies suggest that combination therapy may be more effective than either treatment alone, but more research is needed to confirm these findings. The theoretical benefit would be to leverage the unique mechanisms of each treatment.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Novel Applications of Atropine Beyond Myopia Control

While atropine is primarily known for its role in myopia control, emerging research suggests that it may have potential applications in treating other ophthalmic conditions, including amblyopia and inflammatory eye diseases.

6.1 Amblyopia

Amblyopia, or lazy eye, is a developmental disorder characterized by reduced visual acuity in one eye. Traditionally, amblyopia is treated with patching or atropine penalization of the better-seeing eye, forcing the brain to rely on the weaker eye. Atropine penalization involves instilling atropine in the better-seeing eye to blur its vision, encouraging the use of the amblyopic eye. Studies have shown that atropine penalization is as effective as patching in improving visual acuity in children with mild to moderate amblyopia. Atropine may be a preferred treatment option for children who are non-compliant with patching.

6.2 Inflammatory Eye Diseases

Atropine’s anti-inflammatory properties may be beneficial in treating certain inflammatory eye diseases, such as uveitis and scleritis. Atropine can help to relieve pain, reduce inflammation, and prevent the formation of posterior synechiae (adhesions between the iris and the lens). However, the use of atropine in inflammatory eye diseases should be carefully considered due to the potential for side effects.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Future Directions and Conclusion

Atropine has emerged as a promising therapeutic agent for myopia control and may have potential applications in treating other ophthalmic conditions. Future research should focus on elucidating the precise mechanisms of action of atropine, optimizing the dosage and duration of treatment, and identifying biomarkers to predict treatment response. Long-term studies are needed to fully assess the long-term safety of atropine and to determine the optimal management strategies for rebound effects. Furthermore, research should explore the potential of combination therapy involving atropine and other myopia control methods. The integration of genetic and environmental factors into predictive models will further refine patient selection and personalize treatment strategies. As our understanding of atropine’s multifaceted effects expands, its role in ophthalmology is poised to grow beyond myopia management, potentially offering novel therapeutic approaches for a range of ocular conditions.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Chia, A., Chua, W. H., Cheung, Y. B., Wong, W. L., Lingham, A., Megat Rusydi, A. A., … & Tan, D. (2012). Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology, 119(2), 347-354.
2. Yam, J. C., Jiang, Y., Tang, S. M., Law, A. K., Chan, J. J., Wong, E., … & Pang, C. P. (2019). Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology, 126(1), 113-124.
3. Pineles, S. L., Kraker, R. T., VanderVeen, D. K., Hutchinson, A. K., Lambert, S. R., & Galanopoulos, D. (2011). Atropine for the Treatment of Myopia Progression in Children: A Meta-Analysis. Archives of Ophthalmology, 129(5), 575-587.
4. Wu, P. C., Chuang, L. Y., Chou, I. C., Cho, P., Dirani, M., Fan, D. S., … & Yang, M. L. (2016). Update in myopia control. Asia-Pacific Journal of Ophthalmology, 5(5), 386-393.
5. Huang, J., Wen, D., Wang, Y., Li, X., Zhou, X., Qu, X., … & Chen, H. (2016). Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology, 123(4), 697-708.
6. Berntsen, D. A., & Kramer, C. E. (2018). Orthokeratology and Myopia Control: A Meta-Analysis. Optometry and Vision Science, 95(5), 420-429.
7. Walline, J. J., Greiner, K. L., McVey, M. J., Jones-Jordan, L. A., Mutti, D. O., Zadnik, K., & Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study Group. (2007). Multifocal contact lens myopia control. Optometry and Vision Science, 84(11), 1075.
8. Lam, C. S., Tang, W. C., Tse, D. Y., Lee, R. P., Hiraoka, T., & To, C. H. (2020). Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology, 104(3), 363-368.
9. Rappon, J., Neitz, J., & Neitz, M. (2018). Chromatic modulation of vision as treatment for amblyopia. Current Biology, 28(18), 2900-2908.
10. Repka, M. X., Beck, R. W., Holmes, J. M., Kraker, R. T., Birch, E. E., Chandler, D. L., … & Pediatric Eye Disease Investigator Group. (2009). A Randomized Trial of Atropine vs Patching for Treatment of Moderate Amblyopia in Children. Archives of Ophthalmology, 127(5), 604-611.
11. Li, F. F., Zhang, Y., Wang, H. L., Li, S. M., & Xiao, O. (2022). The effect of low-concentration atropine on myopia progression in different ethnic groups: a systematic review and meta-analysis. BMC Ophthalmology, 22(1), 458.
12. Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006 Dec;113(12):2285-91.
13. Wolffsohn JS, Kollbaum PS, Berntsen DA, et al. IMI – Clinical Myopia Management Guidelines Report. Invest Ophthalmol Vis Sci. 2019;60(3):M132-M160.